Should I Buy IMNM? IMNM 2026 Analysis

Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

24.880

1 Day change

3.67%

52 Week Range

27.650

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: the primary trend is bullish (SMA_5 > SMA_20 > SMA_200) and sentiment (analysts + options + insider/hedge activity) is strongly positive.
Near-term trade setup: price (26.35) is just below resistance (R1 ~27.19); a push through that level improves odds of continuation, while pivot support is ~25.67.
Intellectia signals: no AI Stock Picker or SwingMax “strong buy” trigger today, so this is a discretionary buy based on trend + sentiment rather than a proprietary signal day.
No politician/congress activity flagged recently, so nothing to contradict the bullish positioning.
Earnings (2026-02-12 AH) is the next major catalyst window; with an impatient profile, entering before that is still justified given the current uptrend and bullish positioning.

Technical Analysis

Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend.
Momentum: MACD histogram at +0.16 (above zero) but “positively contracting” suggests upside momentum is moderating rather than accelerating.
RSI (6): 65.8 (upper-neutral); not overbought, but closer to the “hot” zone, implying less attractive risk/reward than a pullback entry.
Key levels: Pivot 25.67 (near-term line in the sand). Resistance R1 27.19 then R2 28.13; supports S1 24.15 then S2 23.21.
Quant-style short horizon read (pattern analog): indicates modest negative drift probabilities (-0.79% next week, -4.34% next month), so expect chop/pullbacks even within a larger uptrend.
Intellectia Proprietary Trading Signals:
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/Call OI ratio 0.33 is call-heavy (bullish skew); put volume is extremely low vs calls (volume put-call ratio 0.02).
Activity: Today’s option volume 157 is elevated vs average (today vs 30D avg ~18.32), suggesting increased attention.
Volatility: 30D IV ~90.47 vs historical vol ~56.14 (options pricing in sizable moves).
IV percentile/rank: IV percentile ~27 and IV rank ~17 are relatively low vs the stock’s own recent history, implying options are not “max expensive” despite high absolute IV (more supportive of bullish positioning than panic hedging).

Technical Summary

Sell

Buy

Positive Catalysts

- Strong Wall Street momentum after Phase 3 RINGSIDE top-line success for varegacestat (desmoid tumors), with multiple firms raising price targets sharply and reiterating Buy/Outperform.
- Ownership/flow: Hedge funds reported as net buyers (buying amount +577% last quarter) and insiders buying (+113% last month), which typically supports upside follow-through.
- Upcoming event: QDEC 2025 earnings on 2026-02-12 (AH) can act as a volatility/catalyst window if pipeline/launch execution commentary is constructive.

Neutral/Negative Catalysts

- No fresh news in the last week, so the stock may drift/mean-revert short term after the earlier Phase 3-driven repricing.
- Options imply big moves (high absolute IV), and the short-horizon pattern model points to slightly negative expected drift over the next week/month.
- Event risk: earnings (2026-02-12 AH) can create downside gaps if cash burn, guidance tone, or commercialization timelines disappoint.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: fell to 0 (-100% YoY), consistent with a clinical-stage profile and not yet commercialized.
Profitability: Net income improved to -$57.46M (loss narrowed ~21.99% YoY), which is directionally positive for burn management.
EPS: -0.65 (worse by ~16.67% YoY), a negative datapoint versus the net income improvement (could reflect share count/other items).
Takeaway: fundamentals remain “development-stage”; the stock is trading primarily on clinical/regulatory/commercial execution expectations rather than current revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: decisively positive—multiple price target raises clustered around mid-Dec 2025 following positive Phase 3 results.
Key updates: Guggenheim PT to $35 (Buy), Evercore ISI to $40 (Outperform), Lake Street to $32 (Buy), Leerink to $40 (Outperform), Stephens to $33 (Overweight).
Wall Street pros view (bull case): high approval likelihood and potential to be a class/market leader in desmoid tumors with sizable peak revenue potential (often framed as ~$780M to $1B+ opportunity).
Wall Street cons view (bear/risks highlighted): commercialization execution and questions like treatment duration dynamics for the class (i.e., real-world usage/market capture variables) remain key uncertainties.

11 Analyst Rating

Wall Street analysts forecast IMNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 33.2 USD with a low forecast of 21 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.000

Low

Averages

33.2

High

Current: 24.000

Low

Averages

33.2

High

Guggenheim

Buy

upgrade

$25 -> $35

AI Analysis

2025-12-16

Reason

Guggenheim

Price Target

$25 -> $35

AI Analysis

2025-12-16

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Immunome to $35 from $25 and keeps a Buy rating on the shares after the company reported positive top-line Phase 3 trial results for varegacestat. The firm believes approval likelihood is high and that varegacestat is well-positioned to capture the majority share in the a potential $1B-$2B DT market in the U.S.

Evercore ISI

NULL

Outperform

upgrade

$18 -> $40

2025-12-16

Reason

Evercore ISI

Price Target

$18 -> $40

2025-12-16

upgrade

NULL

Outperform

Reason

Evercore ISI raised the firm's price target on Immunome to $40 from $18 and keeps an Outperform rating on the shares. The "overwhelmingly positive" results from the RINGSIDE trial bolstered confidence in varegacestat's potential as a leading treatment for desmoid tumors, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNM

Unlock Now

IMNM Should I Buy

IMNM Should I Buy

Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch